ClinicalTrials.gg
CompletedNCT01584232Updated Oct 20, 2014Results posted

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus

A Phase 3 interventional study of LY2189265 and Insulin glargine in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 15 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-10-20.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
361
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
19th of 54
361 · median 159
Started
2012
with 7 others
Phase 3
22 of 54
1 open now
Registered
22nd of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 19th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 3, and was the 22nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 (dulaglutide) in participants with type 2 diabetes mellitus taking an oral antihyperglycemic medication (OAM).

Read the detailed description

Rescue therapy (defined as alternative antihyperglycemic medication use or dose modification of oral antihyperglycemic medication [OAM]) may have been initiated during the planned treatment period if the participant discontinued study drug or met prespecified thresholds for severe, persistent hyperglycemia. Efficacy data, as well as data for hypoglycemic episodes from participants who permanently discontinued study treatment but switched to another diabetes medication and remained in the study, were censored from the point of initiating new treatment onwards.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Glucagon-like peptide-1 (GLP-1)
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have had a diagnosis of type 2 diabetes mellitus for at least 6 months before screening
  • Participants who have been taking sulfonylurea (glibenclamide, gliclazide, or glimepiride) and/or biguanide (metformin or buformin). The dose of the drug(s) during the 8 weeks before screening must be stable
  • Participants who have a qualifying glycosylated () value of 7.0% to 10.0% at screening
  • Participants who have a (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

  • Participants who have a diagnosis of type 1 diabetes
  • Participants who have previously been treated with any other glucagon-like peptide 1 (GLP-1) analog
  • Participants who have received therapy with an alpha-glucosidase inhibitor (a-GI), thiazolidinedione (TZD), glinide, or dipeptidyl peptidase-IV (DPP-IV) inhibitor within 3 months before screening
  • Participants who have been currently taking insulin or have had previous insulin treatment within 3 months before screening
  • Participants who have obvious clinical signs or symptoms of pancreatitis, a history of chronic pancreatitis, or acute pancreatitis at screening, as determined by the investigator. Participants who have a serum amylase concentration ≥ 3 times the upper limit of the reference range and/or a serum lipase concentration ≥ 2 times the upper limit of the reference range, as determined by the central laboratory at screening
  • Participants who have self or family history of medullary C-cell hyperplasia, focal hyperplasia, or medullary thyroid carcinoma (MTC)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
361 participants (actual)

Study arms

  • Experimental
    LY2189265 + OAM

    LY2189265: 0.75 milligrams (mg), administered subcutaneously (SC), once weekly for 26 weeks Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin).

    Drug: LY2189265 · Drug: Sulfonylureas (SU) · Drug: Biguanide (BG)

  • Active comparator
    Insulin glargine + OAM

    Insulin glargine: dose based on targeting fasting blood glucose ≤110 milligrams per deciliter (mg/dL), administered subcutaneously (SC), once daily for 26 weeks Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin).

    Drug: Insulin glargine · Drug: Sulfonylureas (SU) · Drug: Biguanide (BG)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks

    Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.

    Time frame: Baseline, 26 weeks

Secondary outcomes

  1. Percentage of Participants Who Achieved Glycosylated Hemoglobin (HbA1c) <=6.5% or <7% at 26 Weeks

    The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a longitudinal logistic regression model with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.

    Time frame: Up to 26 weeks

  2. Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks

    Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline FBG as a covariate, and participant as a random effect.

    Time frame: Baseline, 26 weeks

  3. Change From Baseline in 8-Point Self-Monitored Blood Glucose (SMBG) at 26 Weeks

    Participants were to test and record SMBG concentrations in their study diaries before each meal (breakfast, lunch, and dinner), approximately 2 hours after the start of each meal, at bedtime, and before breakfast the next morning (second pre-morning meal). Least squares (LS) means were calculated using analysis of covariance (ANCOVA) model with treatment, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects and baseline SMBG as a covariate.

    Time frame: Baseline, Up to 26 weeks

  4. Change From Baseline in Body Weight at 26 Weeks

    Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline body weight as a covariate, and participant as a random effect.

    Time frame: Baseline, 26 weeks

  5. Percentage of Participants With Hypoglycemic Episodes

    The percentage of participants with hypoglycemic episodes was calculated by dividing the number of participants with at least one hypoglycemic episode over the 26-week treatment period by the total number of participants analyzed, multiplied by 100%. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 Weeks

07

Results

Posted Oct 20, 2014

Participant flow

Participant flow — Overall Study
MilestoneLY2189265 + OAMInsulin Glargine + OAM
Started181180
Received at least 1 dose of study drug181180
Completed173177
Not completed83
Withdrew: Adverse event31
Withdrew: Withdrawal by subject21
Withdrew: Physician decision21
Withdrew: Lost to follow-up10

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks

Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks
percentage of HbA1cLY2189265 + OAMInsulin Glargine + OAM
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks-1.44 ± 0.05-0.90 ± 0.05
Statistical analysis
  • LY2189265 + OAM vs Insulin Glargine + OAM · Mixed Models Analysis · p = <0.001 (P-value is from the pairwise comparison of LS means using a mixed effects model with repeated measurements (MMRM).) · Ls mean difference: -0.54 · 95% CI -0.67 to -0.41
SecondaryPercentage of Participants Who Achieved Glycosylated Hemoglobin (HbA1c) <=6.5% or <7% at 26 Weeks

The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a longitudinal logistic regression model with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline HbA1c as a covariate, and participant as a random effect.

Time frame:
Up to 26 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Glycosylated Hemoglobin (HbA1c) <=6.5% or <7% at 26 Weeks
percentage of participantsLY2189265 + OAMInsulin Glargine + OAM
HbA1c <=6.5%51.124.0
HbA1c <7%71.345.8
Statistical analysis
  • LY2189265 + OAM vs Insulin Glargine + OAM · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c \<=6.5%.)
  • LY2189265 + OAM vs Insulin Glargine + OAM · Regression, Logistic · p = <0.001 (Treatment comparison for HbA1c \<7%.)
SecondaryChange From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks

Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline FBG as a covariate, and participant as a random effect.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks
milligrams per deciliter (mg/dL)LY2189265 + OAMInsulin Glargine + OAM
Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks-34.3 ± 1.9-37.8 ± 1.9
Statistical analysis
  • LY2189265 + OAM vs Insulin Glargine + OAM · Mixed Models Analysis · p = 0.183 · Ls mean difference: 3.5 · 95% CI -1.7 to 8.7
SecondaryChange From Baseline in 8-Point Self-Monitored Blood Glucose (SMBG) at 26 Weeks

Participants were to test and record SMBG concentrations in their study diaries before each meal (breakfast, lunch, and dinner), approximately 2 hours after the start of each meal, at bedtime, and before breakfast the next morning (second pre-morning meal). Least squares (LS) means were calculated using analysis of covariance (ANCOVA) model with treatment, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects and baseline SMBG as a covariate.

Time frame:
Baseline, Up to 26 weeks
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in 8-Point Self-Monitored Blood Glucose (SMBG) at 26 Weeks
milligrams per deciliter (mg/dL)LY2189265 + OAMInsulin Glargine + OAM
Pre-morning meal (n=178, 179)-33.49 ± 1.65-38.66 ± 1.64
2 hours post-morning meal (n=178, 179)-49.54 ± 3.33-36.14 ± 3.31
Pre-midday meal (n=178, 179)-36.16 ± 2.68-27.94 ± 2.66
2 hours post-midday meal (n=178, 179)-43.51 ± 3.27-20.30 ± 3.25
Pre-evening meal (n=178, 179)-31.14 ± 2.77-17.50 ± 2.75
2 hours post-evening meal (n=177, 178)-46.68 ± 3.05-15.55 ± 3.03
Bedtime (n=177, 172)-41.53 ± 2.95-17.79 ± 2.96
Second pre-morning meal (n=178, 179)-30.81 ± 1.60-37.02 ± 1.59
Statistical analysis
  • LY2189265 + OAM vs Insulin Glargine + OAM · ANCOVA · p = 0.022 (Treatment comparison for pre-morning meal.) · Ls mean difference: 5.16 · 95% CI 0.76 to 9.56
  • LY2189265 + OAM vs Insulin Glargine + OAM · ANCOVA · p = 0.003 (Treatment comparison for 2 hours post-morning meal.) · Ls mean difference: -13.40 · 95% CI -22.28 to -4.52
  • LY2189265 + OAM vs Insulin Glargine + OAM · ANCOVA · p = 0.025 (Treatment comparison for pre-midday meal.) · Ls mean difference: -8.22 · 95% CI -15.37 to -1.06
  • LY2189265 + OAM vs Insulin Glargine + OAM · ANCOVA · p = <0.001 (Treatment comparison for 2 hours post-midday meal.) · Ls mean difference: -23.22 · 95% CI -31.92 to -14.51
  • LY2189265 + OAM vs Insulin Glargine + OAM · ANCOVA · p = <0.001 (Treatment comparison for pre-evening meal.) · Ls mean difference: -13.63 · 95% CI -21.03 to -6.24
  • LY2189265 + OAM vs Insulin Glargine + OAM · ANCOVA · p = <0.001 (Treatment comparison for 2 hours post-evening meal.) · Ls mean difference: -31.13 · 95% CI -39.26 to -23.00
  • LY2189265 + OAM vs Insulin Glargine + OAM · ANCOVA · p = <0.001 (Treatment comparison for bedtime.) · Ls mean difference: -23.73 · 95% CI -31.68 to -15.79
  • LY2189265 + OAM vs Insulin Glargine + OAM · ANCOVA · p = 0.005 (Treatment comparison for second pre-morning meal.) · Ls mean difference: 6.21 · 95% CI 1.92 to 10.50
SecondaryChange From Baseline in Body Weight at 26 Weeks

Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, visit, treatment-by-visit, oral antihyperglycemic medication regimen (sulfonylureas only, biguanides only, or both), and baseline body mass index (BMI) group (\<25 or \>=25 kilograms per meter squared \[kg/m\^2\]) as fixed effects, baseline body weight as a covariate, and participant as a random effect.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Body Weight at 26 Weeks
kilograms (kg)LY2189265 + OAMInsulin Glargine + OAM
Change From Baseline in Body Weight at 26 Weeks-0.48 ± 0.170.94 ± 0.17
Statistical analysis
  • LY2189265 + OAM vs Insulin Glargine + OAM · Mixed Models Analysis · p = <0.001 · Ls mean difference: -1.42 · 95% CI -1.89 to -0.94
SecondaryPercentage of Participants With Hypoglycemic Episodes

The percentage of participants with hypoglycemic episodes was calculated by dividing the number of participants with at least one hypoglycemic episode over the 26-week treatment period by the total number of participants analyzed, multiplied by 100%. All classifications of hypoglycemia (documented symptomatic, asymptomatic, severe, nocturnal, non-nocturnal, probable symptomatic, relative, and unspecified) were included, except for episodes of relative hypoglycemia that were not severe. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Hypoglycemic Episodes
percentage of participantsLY2189265 + OAMInsulin Glargine + OAM
Percentage of Participants With Hypoglycemic Episodes26.047.8
Statistical analysis
  • LY2189265 + OAM vs Insulin Glargine + OAM · Fisher Exact · p = <0.001

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY2189265 + OAM—9/181 (5%)133/181 (73.5%)
Insulin Glargine + OAM—3/180 (1.7%)111/180 (61.7%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventLY2189265 + OAMInsulin Glargine + OAM
Cerebral infarctionNervous system disorders2/1810/180
Anal abscessInfections and infestations0/1811/180
Spinal cord infarctionNervous system disorders0/1811/180
Viith nerve paralysisNervous system disorders0/1811/180
Acute myocardial infarctionCardiac disorders1/1810/180
CholelithiasisHepatobiliary disorders1/1810/180
Hyperplastic cholecystopathyHepatobiliary disorders1/1810/180
Urinary tract infectionInfections and infestations1/1810/180
FallInjury, poisoning and procedural complications1/1810/180
Patella fractureInjury, poisoning and procedural complications1/1810/180
Most frequent other events
Showing 10 of 165
Most frequent other events
EventLY2189265 + OAMInsulin Glargine + OAM
NasopharyngitisInfections and infestations49/18146/180
DiarrhoeaGastrointestinal disorders22/1814/180
NauseaGastrointestinal disorders17/1812/180
ConstipationGastrointestinal disorders16/1816/180
VomitingGastrointestinal disorders9/1812/180
Lipase increasedInvestigations9/1811/180
BronchitisInfections and infestations4/1817/180
HypertensionVascular disorders6/1816/180
InfluenzaInfections and infestations6/1812/180
Back painMusculoskeletal and connective tissue disorders5/1815/180

Baseline characteristics

All randomized participants who received at least 1 dose of LY2189265 or insulin glargine.

Age, Continuous
Age, Continuous(years)LY2189265 + OAMInsulin Glargine + OAMTotal
Mean57.52 ± 10.4856.14 ± 11.3356.83 ± 10.92
Sex: Female, Male
Sex: Female, Male(Participants)LY2189265 + OAMInsulin Glargine + OAMTotal
Female5647103
Male125133258
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)LY2189265 + OAMInsulin Glargine + OAMTotal
Asian181180361
Region of Enrollment
Region of Enrollment(participants)LY2189265 + OAMInsulin Glargine + OAMTotal
Japan181180361
08

Study locations

15 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aichi, 448-0852, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 286-0048, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ehime, 790-0024, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 819-0168, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hokkaido, 0530018, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kagoshima, 8910401, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 247-0055, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kumamoto, 860-0811, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kyoto, 606-8397, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagano, 385-0022, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagasaki, 857-1195, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ooita, 8700039, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 598-0048, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 103-0028, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yamaguchi, 754-0002, Japan
09

References and documents

Publications

  • Suzuki S, Oura T, Takeuchi M, Boye KS. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies. Health Qual Life Outcomes. 2017 Jun 12;15(1):123. doi: 10.1186/s12955-017-0696-7. PubMed 28606095 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year 3 months after primary completion. A results delay was requested in Sep 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2012
First posted
Apr 24, 2012
Start
Apr 2012
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Results delay requested
Sep 27, 2013
Results first posted
Oct 20, 2014
Last update
Oct 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01584232
Responsible party
Sponsor
First posted
Apr 24, 2012
Start date
Apr 2012
Primary completion
Jul 2013
Completion
Jul 2013
Results posted
Oct 20, 2014
Last update
Oct 20, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion